MediciNova to Present at the LD Micro Main Event XIX Investor Conference
MWN-AI** Summary
MediciNova, Inc., a biopharmaceutical company listed on NASDAQ under the ticker MNOV and on the Tokyo Stock Exchange (Code: 4875), is set to present at the LD Micro Main Event XIX Investor Conference in San Diego, California, from October 19-22, 2025. The company, which focuses on developing innovative small molecule therapies for inflammatory, fibrotic, and neurodegenerative disorders, will have its President and CEO, Dr. Yuichi Iwaki, and Chief Business Officer, Dr. David H. Crean, giving a corporate overview on October 20 at 1:30 PM Pacific Time.
Investors can access the presentation through a live webcast on MediciNova's investor relations website, which will also host a replay of the discussion for 90 days following the event. In addition to the presentation, Drs. Iwaki and Crean will be available for one-on-one meetings with attendees throughout the conference.
MediciNova's pipeline includes 11 clinical programs centered around two key compounds: MN-166 (ibudilast) and MN-001 (tipelukast). MN-166 is currently in Phase 3 trials targeting amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), with additional evaluations for Long COVID and substance dependence in Phase 2 trials. Meanwhile, MN-001 has been assessed in Phase 2 for idiopathic pulmonary fibrosis (IPF), with an ongoing trial for non-alcoholic fatty liver disease (NAFLD).
Despite promising developments, the company highlights that future statements regarding its products' efficacy are forward-looking and subject to various risks, including funding for clinical development and regulatory approvals. Investors are encouraged to review MediciNova’s filings with the SEC for a comprehensive understanding of potential risks and uncertainties.
MWN-AI** Analysis
As MediciNova, Inc. (NASDAQ: MNOV) approaches its presentation at the LD Micro Main Event XIX Investor Conference, it presents an intriguing opportunity for investors keen on biopharmaceuticals. The event, scheduled for October 20, 2025, will showcase the promising advancements of MediciNova’s two lead compounds, MN-166 (ibudilast) and MN-001 (tipelukast), both of which hold substantial therapeutic potential in addressing severe health conditions.
Investors should closely monitor the outcomes of MN-166, which is in Phase 3 trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is Phase 3-ready for progressive multiple sclerosis (MS). The implications of success for MN-166 are significant, as it could lead to substantial market penetration in the lucrative neurology sector. Additionally, the ongoing Phase 2 trials for Long COVID and substance dependence highlight the compound's versatility and market appeal, given the increasing focus on these conditions post-pandemic.
On the other hand, MN-001’s trials in idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver disease (NAFLD), while currently in Phase 2, represent potential growth avenues as the market for effective treatments in these areas expands.
However, investors must weigh these opportunities against inherent risks, including clinical trial uncertainties, funding challenges, and the unpredictability of regulatory approvals. The company's successful track record of securing investigator-sponsored clinical trials through government funding is a positive indicator, yet careful scrutiny of their financial health and funding strategies is advisable.
In summary, MediciNova presents a compelling case for investment within the biopharmaceutical landscape, driven by its innovative pipeline and growth potential—but investors should remain cautious and informed about the associated risks. Consider attending the conference or accessing the webcast to gain deeper insights into the company’s strategic direction and operational updates.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will present a corporate overview at the LD Micro Main Event XIX Investor Conference. The conference is being held on October 19 – 22, 2025 at the Hotel Del Coronado in San Diego, CA.
| Presentation Date: | Monday, October 20, 2025 |
| Time: | 1:30pm Pacific Time |
| Register to view presentation: | Webcast Link |
A live webcast of the presentation can be accessed on the investor relations section of the MediciNova website. A replay of the webcast will be archived and available following the event for 90 days.
Drs. Iwaki and Crean will be available for one-on-one meetings throughout the conference.
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2024 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
INVESTOR CONTACT :
David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com
FAQ**
What are the key milestones that MediciNova Inc. (MNOV) aims to achieve in the clinical development of MN-166 and MN-001 over the next year?
How does MediciNova Inc. (MNOV) plan to secure future funding or partnerships for the continued development of its late-stage pipeline therapies?
What specific risks does MediciNova Inc. (MNOV) foresee in its ongoing clinical trials, and how is the company preparing to mitigate these risks?
Can you discuss the competitive landscape for MediciNova Inc. (MNOV) in the biopharmaceutical industry, particularly regarding its focus on inflammatory and neurodegenerative diseases?
**MWN-AI FAQ is based on asking OpenAI questions about MediciNova Inc. (NASDAQ: MNOV).
NASDAQ: MNOV
MNOV Trading
5.0% G/L:
$1.47 Last:
11,284 Volume:
$1.43 Open:
